Literature DB >> 18762931

Clinical use of and future perspectives on antiarrhythmic drugs.

Juan Carlos Estrada1, Dawood Darbar.   

Abstract

Cardiac arrhythmias are associated with significant morbidity and mortality. Antiarrhythmic drug therapy was traditionally the mainstay of arrhythmia treatment; however, the limited efficacy and proarrhythmic potential of conventional antiarrhythmic drugs has generated interest in new approaches to the treatment of arrhythmias. Over the last decade, there has been improved characterization of the molecular pathways that culminate in arrhythmias. By analyzing mechanisms that increase susceptibility to arrhythmias in individuals with genetic syndromes, it might be possible to not only improve current therapies but also to develop novel approaches to treat and prevent common arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762931      PMCID: PMC2597182          DOI: 10.1007/s00228-008-0555-x

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  48 in total

1.  Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome.

Authors:  Dawood Darbar; Dan M Roden; Muhammed F Ali; Tao Yang; Mark S Wathen
Journal:  Circulation       Date:  2005-03-22       Impact factor: 29.690

Review 2.  The congenital long QT syndromes from genotype to phenotype: clinical implications.

Authors:  Peter J Schwartz
Journal:  J Intern Med       Date:  2006-01       Impact factor: 8.989

3.  A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization.

Authors:  Dan E Arking; Arne Pfeufer; Wendy Post; W H Linda Kao; Christopher Newton-Cheh; Morna Ikeda; Kristen West; Carl Kashuk; Mahmut Akyol; Siegfried Perz; Shapour Jalilzadeh; Thomas Illig; Christian Gieger; Chao-Yu Guo; Martin G Larson; H Erich Wichmann; Eduardo Marbán; Christopher J O'Donnell; Joel N Hirschhorn; Stefan Kääb; Peter M Spooner; Thomas Meitinger; Aravinda Chakravarti
Journal:  Nat Genet       Date:  2006-04-30       Impact factor: 38.330

4.  ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  Circulation       Date:  2006-08-15       Impact factor: 29.690

5.  Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation.

Authors:  Michael H Gollob; Douglas L Jones; Andrew D Krahn; Lynne Danis; Xiang-Qun Gong; Qing Shao; Xiaoqin Liu; John P Veinot; Anthony S L Tang; Alexandre F R Stewart; Frederique Tesson; George J Klein; Raymond Yee; Allan C Skanes; Gerard M Guiraudon; Lisa Ebihara; Donglin Bai
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

Review 6.  Is atrial fibrillation an inflammatory disorder?

Authors:  Christopher J Boos; Richard A Anderson; Gregory Y H Lip
Journal:  Eur Heart J       Date:  2005-11-08       Impact factor: 29.983

Review 7.  The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.

Authors:  Panagiotis Korantzopoulos; Theofilos M Kolettis; Dimitrios Galaris; John A Goudevenos
Journal:  Int J Cardiol       Date:  2006-06-09       Impact factor: 4.164

Review 8.  n-3 Fatty acids, cardiac arrhythmia and fatal coronary heart disease.

Authors:  Ingeborg A Brouwer; Anouk Geelen; Martijn B Katan
Journal:  Prog Lipid Res       Date:  2006-04-18       Impact factor: 16.195

9.  C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion.

Authors:  O Wazni; D O Martin; N F Marrouche; M Shaaraoui; M K Chung; S Almahameed; R A Schweikert; W I Saliba; A Natale
Journal:  Heart       Date:  2005-05-12       Impact factor: 5.994

Review 10.  Brugada syndrome: from cell to bedside.

Authors:  Charles Antzelevitch; Pedro Brugada; Josep Brugada; Ramon Brugada
Journal:  Curr Probl Cardiol       Date:  2005-01       Impact factor: 5.200

View more
  3 in total

1.  QSAR studies on a number of pyrrolidin-2-one antiarrhythmic arylpiperazinyls.

Authors:  Alicja Nowaczyk; Katarzyna Kulig
Journal:  Med Chem Res       Date:  2011-01-07       Impact factor: 1.965

2.  Ibutilide and novel indexes of ventricular repolarization in persistent atrial fibrillation patients.

Authors:  Panagiotis Korantzopoulos; Konstantinos P Letsas; Anna Kotsia; Giannis Baltogiannis; Kallirroi Kalantzi; Konstantinos Kyrlas; John A Goudevenos
Journal:  World J Cardiol       Date:  2013-07-26

3.  Antiarrhythmic and antioxidant activity of novel pyrrolidin-2-one derivatives with adrenolytic properties.

Authors:  Jacek Sapa; Alicja Nowaczyk; Katarzyna Kulig
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-10-15       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.